[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-406352-105":59,"doc-detail-406352-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","levodopa-and-the-dopamine-receptor-d1-hippoyes-associated-protein-axis-a-novel-therapeutic-avenue-for-liver-fibrosis","Levodopa and the dopamine receptor D1-Hippo/yes-associated protein axis - A novel therapeutic avenue for liver fibrosis","","Liver fibrosis is a major global health burden with limited effective therapies. The editorial discusses findings that levodopa, a dopamine precursor used in Parkinson’s disease, attenuates carbon tetrachloride-induced liver fibrosis in rats by increasing dopamine receptor D1 expression and activating the Hippo signaling pathway, resulting in phosphorylation and inactivation of yes-associated protein 1. The work connects G-protein-coupled receptor signaling to Hippo pathway control in hepatic fibrosis and suggests levodopa as a promising repurposed, clinically translatable antifibrotic option.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/levodopa-and-the-dopamine-receptor-d1-hippoyes-associated-protein-axis-a-novel-therapeutic-avenue-for-liver-fibrosis/406352/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/levodopa-and-the-dopamine-receptor-d1-hippoyes-associated-protein-axis-a-novel-therapeutic-avenue-for-liver-fibrosis/406352.png","ImageObject",300,407,{"name":92,"@type":93},"Rizky","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What mechanism links levodopa to reduced liver fibrosis in the reported study?","Question",{"text":113,"@type":114},"Levodopa increases dopamine receptor D1 expression and activates the Hippo signaling pathway, leading to phosphorylation and inactivation of yes-associated protein 1, which helps suppress fibrotic progression.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why is liver fibrosis considered a critical clinical problem?",{"text":118,"@type":114},"It is described as the final common pathway of many chronic liver injuries, driven by cycles of injury, inflammation, and repair, eventually progressing to cirrhosis and major complications.",{"name":120,"@type":111,"acceptedAnswer":121},"How does levodopa fit into translational prospects for chronic liver disease?",{"text":122,"@type":114},"Because levodopa is already clinically used with an established safety record and affordability, the editorial highlights its potential as a rapidly translatable repurposing candidate, pending validation in human tissues and diverse fibrosis models.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},406352,1790961605,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","| W | J | G | World Journal of\u003Cbr>Gastroenterology |\n| --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Gastroenterol 2025 December 14; 31(46): 113298  \nDOI: 10.3748/wjg.v31.i46.113298 ISSN 1007-9327 (print) ISSN 2219-2840 (online)  \nEDITORIAL  \nLevodopa and the dopamine receptor D1-Hippo/yes-associated protein axis: A novel therapeutic avenue for liver fibrosis  \nShan-Shan Xie, Zhi-Gang Liu  \nSpecialty type: Gastroenterology and hepatology  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade A, Grade B, Grade B  \nNovelty: Grade A, Grade B, Grade B  \nCreativity or Innovation: Grade A, Grade B, Grade B  \nScientific Significance: Grade A, Grade B, Grade B  \nP-Reviewer: Kim JW, PhD, Assistant Professor, South Korea; Wang JL, PhD, Associate Professor, China  \nReceived: August 21, 2025  \nRevised: October 9, 2025  \nAccepted: October 31, 2025  \nPublished online: December 14, 2025  \nProcessing time: 111 Days and 16.1 Hours  \nShan-Shan Xie, Zhi-Gang Liu, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, Zhejiang Province, China  \nShan-Shan Xie, Zhi-Gang Liu, Zhejiang Key Laboratory of Neonatal Diseases, Hangzhou 310052, Zhejiang Province, China  \nShan-Shan Xie, Department of Cell Biology, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang Province, China  \nZhi-Gang Liu, Department of Metabolism, Digestion and Reproduction, Imperial College London, London SW7 2AZ, United Kingdom  \nCo-corresponding authors: Shan-Shan Xie and Zhi-Gang Liu.  \nCorresponding author: Shan-Shan Xie, Professor, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, No. 3333 Binsheng Road, Binjiang District, Hangzhou 310052, Zhejiang Province, [China.](China. sxie@zju.edu.cn)[ sxie@zju.edu.cn](China. sxie@zju.edu.cn)  \nAbstract  \nLiver fibrosis remains a major global health challenge with limited therapeutic options. In their recent study, Wang et al report that levodopa, a dopamine precursor widely used in Parkinson’s disease, significantly attenuates carbon tetrachloride-induced liver fibrosis in rats by enhancing dopamine receptor D1 expression and activating the Hippo signaling pathway, leading to phosphorylation and inactivation of yes-associated protein 1. This discovery links Gprotein-coupled receptor signaling to Hippo pathway regulation in hepatic fibrosis. The work highlights the dopamine receptor D1-Hippo/yes-associated protein 1 axis as a promising antifibrotic mechanism and introduces levodopa as a potential repurposing candidate for chronic liver disease. With its established safety and affordability, levodopa offers a rapidly translatable strategy that warrants validation in human tissues and diverse fibrosis models. Here, we place these findings in the broader context of G-protein-coupled receptor regulation of hepatic stellate cell activation, discuss translational opportunities for levodopa in liver fibrosis, and propose future directions to validate this pathway across disease models and clinical settings.  \nKey Words: Levodopa; Liver fibrosis; Dopamine receptor D1; Hippo signaling pathway;  \n WJG  [https://www.wjgnet.com](https://www.wjgnet.com) 1 December 14, 2025  Volume 31  Issue 46   \nXie SS et al. Repurposing levodopa for liver fibrosis  \nYes-associated protein; Drug repurposing; Hepatic stellate cell; G-protein coupled receptor  \n©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.  \nCore Tip: This editorial highlights a novel mechanistic insight from a recent study by Wang et al, which identifies the dopamine precursor levodopa, a mainstay Parkinson’s disease therapy, as a potent inhibitor of liver fibrosis in experimental models. The antifibrotic effect is mediated th","cbCaimrGp2yCDZJT","https://ap.wps.com/l/cbCaimrGp2yCDZJT","pdf",394361,"English","# Editorial\n## Levodopa and the dopamine receptor D1-Hippo/yes-associated protein axis: A novel therapeutic avenue for liver fibrosis\n## Abstract\n## Core Tip\n## Introduction\n## Liver fibrosis as a final common pathway","[{\"question\":\"What mechanism links levodopa to reduced liver fibrosis in the reported study?\",\"answer\":\"Levodopa increases dopamine receptor D1 expression and activates the Hippo signaling pathway, leading to phosphorylation and inactivation of yes-associated protein 1, which helps suppress fibrotic progression.\"},{\"question\":\"Why is liver fibrosis considered a critical clinical problem?\",\"answer\":\"It is described as the final common pathway of many chronic liver injuries, driven by cycles of injury, inflammation, and repair, eventually progressing to cirrhosis and major complications.\"},{\"question\":\"How does levodopa fit into translational prospects for chronic liver disease?\",\"answer\":\"Because levodopa is already clinically used with an established safety record and affordability, the editorial highlights its potential as a rapidly translatable repurposing candidate, pending validation in human tissues and diverse fibrosis models.\"}]","Levodopa and the dopamine receptor D1-Hippo/yes-associated protein axis - A novel therapeutic avenue for liver fibrosis | PDF",1790565074,18]